Targeting memory processes with drugs to prevent or cure PTSD

Expert Opinion on Investigational Drugs

Volumn 21, Issue 9, 2012, Pages 1323-1350

  Cain, Christopher K ^a,b   Maynard, George D ^c   Kehne, John H ^d  

^a NEW YORK UNIVERSITY   (United States)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^c Axerion Therapeutics   (United States)

^d Translational Neuropharmacology Consulting   (United States)

Author keywords

Amygdala; Drugs; Fear conditioning; Prefrontal cortex; PTSD; Stress; Therapy

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMFEBUTAMONE; AMITRIPTYLINE; ARIPIPRAZOLE; BUSPIRONE; CLONIDINE; CYCLOSERINE; DULOXETINE; GABAPENTIN; GUANFACINE; HYDROCORTISONE; IMIPRAMINE; KETAMINE; LAMOTRIGINE; MIRTAZAPINE; MORPHINE; NALMEFENE; NALTREXONE; NEFAZODONE; OLANZAPINE; PRAZOSIN; PROPRANOLOL; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TIAGABINE; TOPIRAMATE; UNINDEXED DRUG; VALPROATE SEMISODIUM; VENLAFAXINE;

AVERSION; CONDITIONING; DRUG ACTIVITY; DRUG MECHANISM; DRUG TARGETING; FEAR; HUMAN; MEMORY; NEUROBIOLOGY; POSTTRAUMATIC STRESS DISORDER; PSYCHOTHERAPY; REVIEW; STRESS; TREATMENT DURATION;

ANIMALS; COMBINED MODALITY THERAPY; CONDITIONING (PSYCHOLOGY); FEAR; HUMANS; MEMORY; MOLECULAR TARGETED THERAPY; NEURONAL PLASTICITY; PSYCHOTHERAPY; STRESS DISORDERS, POST-TRAUMATIC;

EID: 84865322844     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.704020     Document Type: Review

References (217)

1. Friedman MJ, Resick PA, Bryant RA, Brewin CR. Considering ptsd for dsm-5. Depress Anxiety 2011;28(9):750-69
2. Friedman MJ, Resick PA, Bryant RA, et al. Classification of trauma and stressor-related disorders in dsm-5. Depress Anxiety 2011;28(9):737-49
3. Foa EB. Psychosocial therapy for posttraumatic stress disorder. J Clin Psychiatry 2006;67(Suppl 2):40-5 (Pubitemid 43268188)
4. Kowalik J, Weller J, Venter J, Drachman D. Cognitive behavioral therapy for the treatment of pediatric posttraumatic stress disorder: a review and meta-analysis. J Behav Ther Exp Psychiatry 2011;42(3):405-13
5. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-ofonset distributions of dsm-iv disorders in the national comorbidity survey replication. Arch Gen Psychiatry 2005;62(6):593-602 (Pubitemid 40973434)
6. Brunello N, Davidson JR, Deahl M, et al. Posttraumatic stress disorder: diagnosis and epidemiology, comorbidity and social consequences, biology and treatment. Neuropsychobiology 2001;43(3):150-62 (Pubitemid 32268586)
7. Hoge CW, Castro CA, Messer SC, et al. Combat duty in iraq and afghanistan, mental health problems and barriers to care. US Army Medical Department journal 2008;7-17
8. McFarlane AC, Williamson P, Barton CA. The impact of traumatic stressors in civilian occupational settings. J Public Health Policy 2009;30(3):311-27
9. Ledford H. Neuroscientists unite for. 'moon shot'. Nature 2011. doi:10.1038/news.2011.324
10. Shalev AY. PTSD: A disorder of recovery? In: Kirmayer L, Lemelson R, Barad M, editors. Understanding trauma: integrating biological, clinical, and cultural perspectives. Cambridge University Press; New York, NY: 2007. p. 207-23
11. Yehuda R. Risk and resilience in posttraumatic stress disorder. J Clin Psychiatry 2004;65(Suppl 1):29-36
12. Charney DS. Neuroanatomical circuits modulating fear and anxiety behaviors. Acta Psychiatr Scand Suppl 2003;417:38-50
13. Ressler KJ, Mercer KB, Bradley B, et al. Post-traumatic stress disorder is associated with pacap and the pac1 receptor. Nature 2011;470(7335):492-7
14. Marmar CR, McCaslin SE, Metzler TJ, et al. Predictors of posttraumatic stress in police and other first responders. Ann NY Acad Sci 2006(1071):1-18 (Pubitemid 44126715)
15. Heim C, Nemeroff CB. Neurobiology of early life stress: clinical studies. Semin Clin Neuropsychiatry 2002;7(2):147-59
16. Nemeroff CB, Bremner JD, Foa EB, et al. Posttraumatic stress disorder: a state-of-the-science review.J Psychiatr Res 2006;40(1):1-21
17. Yehuda R, LeDoux J. Response variation following trauma: a translational neuroscience approach to understanding ptsd. Neuron 2007;56(1):19-32 (Pubitemid 47484180)
18. Gillespie CF, Phifer J, Bradley B, Ressler KJ. Risk and resilience: genetic and environmental influences on development of the stress response. Depress Anxiety 2009;26(11):984-92
19. Southwick SM, Vythilingam M, Charney DS. The psychobiology of depression and resilience to stress: Implications for prevention and treatment. Annu Rev Clin Psychol 2005;1:255-91 (Pubitemid 43843952)
20. DavisM, Barad M, Otto M, Southwick S. Combining pharmacotherapy with cognitive behavioral therapy: traditional and new approaches. J Trauma Stress 2006;19(5):571-81 (Pubitemid 46424373)
21. Kozaric-Kovacic D. Pharmacotherapy treatment of ptsd and comorbid disorders. Psychiatr Danub 2009;21(3):411-14
22. Delahanty DL, Nugent NR. Predicting ptsd prospectively based on prior trauma history and immediate biological responses. Ann NY Acad Sci 2006;1071:27-40 (Pubitemid 44126717)
23. Fanselow MS, Lester LS. A functional behavioristic approach to aversively motivated behavior: predatory imminence as a determinant of the topography of defensive behavior. In: Bolles RC, Beecher MD, editors. Evolution and learning. Hillsdale, NJ: Erlbaum; 1988. p. 185-211
24. Blanchard DC, Yang M, Herbert M, Blanchard RJ. Defensive behaviors. In: Fink G, editor. Encyclopedia of stress. Oxford: Academic Press; 2007. p. 722-26
25. Selye H. The stress of life. McGraw-Hill; New York: 1978
26. Southwick SM, Bremner JD, Rasmusson A, et al. Role of norepinephrine in the pathophysiology and treatment of posttraumatic stress disorder. Biol Psychiatry 1999;46(9):1192-204 (Pubitemid 30114437)
27. Arborelius L, Owens MJ, Plotsky PM, Nemeroff CB. The role of corticotropinreleasing factor in depression and anxiety disorders. J Endocrinol 1999;160(1):1-12 (Pubitemid 29044562)
28. Kehne JH, Cain CK. Therapeutic utility of non-peptidic crf1 receptor antagonists in anxiety, depression, and stress-related disorders: evidence from animal models. Pharmacol Ther 2010;128(3):460-87
29. Kasckow JW, Baker D, Geracioti TD Jr. Corticotropin-releasing hormone in depression and post-traumatic stress disorder. Peptides 2001;22(5):845-51 (Pubitemid 32397737)
30. Yehuda R. Post-traumatic stress disorder. N Engl J Med 2002;346(2):108-14 (Pubitemid 34438902)
31. Karatsoreos IN, McEwen BS. Psychobiological allostasis: resistance, resilience and vulnerability. Trends Cogn Sci 2011;15(12):576-84
32. Gale GD, Anagnostaras SG, Godsil BP, et al. Role of the basolateral amygdala in the storage of fear memories across the adult lifetime of rats. J Neurosci 2004;24(15):3810-15 (Pubitemid 38509411)
33. LeDoux J. Rethinking the emotional brain. Neuron 2012;73(4):653-76
34. Maren S. Neurobiology of pavlovian fear conditioning. Annu Rev Neurosci 2001;24:897-931
35. Rodrigues SM, Schafe GE, LeDoux JE. Molecular mechanisms underlying emotional learning and memory in the lateral amygdala. Neuron 2004;44(1):75-91 (Pubitemid 39348831)
36. Johansen JP, Cain CK, Ostroff LE, LeDoux JE. Molecular mechanisms of fear learning and memory. Cell 2011;147(3):509-24
37. Cain CK, LeDoux JE, In: Nutt DJ, Blanchard RJ, Blanchard DC, Griebel G, editors. Handbook of anxiety and fear 17. Elsevier Academic Press; Amsterdam:2008. p. 103-25
38. Sigurdsson T, Doyere V, Cain CK, LeDoux JE. Long-term potentiation in the amygdala: a cellular mechanism of fear learning and memory. Neuropharmacology 2007;52(1):215-27 (Pubitemid 46026826)
39. Rumpel S, LeDoux J, Zador A, Malinow R. Postsynaptic receptor trafficking underlying a form of associative learning. Science 2005;308(5718):83-8 (Pubitemid 40471002)
40. Balleine BW, Killcross S. Parallel incentive processing: an integrated view of amygdala function. Trends Neurosci 2006;29(5):272-9
41. Milad MR, Quirk GJ. Fear extinction as a model for translational neuroscience: Ten years of progress. Annual review of psychology 2012;63:129-51
42. Josselyn SA. Continuing the search for the engram: examining the mechanism of fear memories. J Psychiatry Neurosci 2010;35(4):221-8
43. Sacktor TC. How does pkmzeta maintain long-term memory? Nat Rev Neurosci 2011;12(1):9-15
44. Parsons RG, Davis M. Temporary disruption of fear-potentiated startle following pkmzeta inhibition in the amygdala. Nat Neurosci 2011;14(3):295-6
45. Sara SJ. Retrieval and reconsolidation: toward a neurobiology of remembering. Learn Mem 2000;7(2):73-84 (Pubitemid 30213021)
46. Nader K, Schafe GE, Le Doux JE. Fear memories require protein synthesis in the amygdala for reconsolidation after retrieval. Nature 2000;406(6797):722-6
47. Suzuki A, Josselyn SA, Frankland PW, et al. Memory reconsolidation and extinction have distinct temporal and biochemical signatures. J Neurosci 2004;24(20):4787-95 (Pubitemid 38668203)
48. Cain CK, Debiec J, LeDoux JE. Consolidation and reconsolidation of pavlovian fear conditioning: roles for intracellular signaling and extracellular modulation in memory storage. In: Fields R, editor. Beyond the synapse: cell-cell signaling in synaptic plasticit. Cambridge University Press; New York, NY: 2008. p. 72-88
49. Lee JL, Milton AL, Everitt BJ. Reconsolidation and extinction of conditioned fear: inhibition and potentiation. J Neurosci 2006;26(39):10051-6 (Pubitemid 44477166)
50. Schiller D, Monfils MH, Raio CM, et al. Preventing the return of fear in humans using reconsolidation update mechanisms. Nature 2010;463(7277):49-53
51. Myers KM, Davis M. Behavioral and neural analysis of extinction. Neuron 2002;36(4):567-84 (Pubitemid 35346753)
52. Pickens CL, Golden SA, Adams-Deutsch T, et al. Long-lasting incubation of conditioned fear in rats. Biol Psychiatry 2009;65(10):881-6
53. Eysenck HJ. A theory of the incubation of anxiety-fear responses. Behav Res Ther 1968;6(3):309-21
54. Debiec J, Bush DE, LeDoux JE. Noradrenergic enhancement of reconsolidation in the amygdala impairs extinction of conditioned fear in rats-a possible mechanism for the persistence of traumatic memories in ptsd. Depress Anxiety 2011;28(3):186-93
55. Bouton ME, Westbrook RF, Corcoran KA, Maren S. Contextual and temporal modulation of extinction: behavioral and biological mechanisms. Biol Psychiatry 2006;60(4):352-60 (Pubitemid 44215847)
56. Likhtik E, Popa D, Apergis-Schoute J, et al. Amygdala intercalated neurons are required for expression of fear extinction. Nature 2008;454(7204):642-5
57. McNally GP, Pigg M, Weidemann G. Opioid receptors in the midbrain periaqueductal gray regulate extinction of pavlovian fear conditioning. J Neurosci 2004;24(31):6912-19 (Pubitemid 39045448)
58. Milad MR, Quirk GJ. Neurons in medial prefrontal cortex signal memory for fear extinction. Nature 2002;420(6911):70-4 (Pubitemid 35291441)
59. Ji J, Maren S. Hippocampal involvement in contextual modulation of fear extinction. Hippocampus 2007;17(9):749-58 (Pubitemid 47493456)
60. Myers KM, Davis M. Mechanisms of fear extinction. Mol Psychiatry 2007;12(2):120-50 (Pubitemid 46160979)
61. Pape HC, Pare D. Plastic synaptic networks of the amygdala for the acquisition, expression, and extinction of conditioned fear. Physiol Rev 2010;90(2):419-63
62. Ostroff LE, Cain CK, Bedont J, et al. Fear and safety learning differentially affect synapse size and dendritic translation in the lateral amygdala. Proc Natl Acad Sci USA 2010;107(20):9418-23
63. Cain CK, LeDoux JE. Escape from fear: a detailed behavioral analysis of two atypical responses reinforced by cs termination. J Exp Psychol Anim Behav Process 2007;33(4):451-63 (Pubitemid 350100767)
64. Lazaro-Munoz G, LeDoux JE, Cain CK. Sidman instrumental avoidance initially depends on lateral and basal amygdale and is constrained by central amygdalamediated pavlovian processes. Biol Psychiatry 2010;67(12):1120-7
65. Ferry B, Roozendaal B, McGaugh JL. Role of norepinephrine in mediating stress hormone regulation of long-term memory storage: a critical involvement of the amygdala. Biol Psychiatry 1999;46(9):1140-52 (Pubitemid 30114433)
66. Bush DE, Sotres-Bayon F, LeDoux JE. Individual differences in fear: isolating fear reactivity and fear recovery phenotypes. J Trauma Stress 2007;20(4):413-22 (Pubitemid 47475492)
67. Yamamoto S, Morinobu S, Takei S, et al. Single prolonged stress: toward an animal model of posttraumatic stress disorder. Depress Anxiety 2009;26(12):1110-17
68. Rau V, DeCola JP, Fanselow MS. Stressinduced enhancement of fear learning: an animal model of posttraumatic stress disorder. Neurosci Biobehav Rev 2005;29(8):1207-23 (Pubitemid 41446896)
69. Roozendaal B, McEwen BS, Chattarji S. Stress, memory and the amygdala. Nat Rev Neurosci 2009;10(6):423-33
70. Yehuda R, Koenen KC, Galea S, Flory JD. The role of genes in defining a molecular biology of ptsd. Dis Markers 2011;30(2-3):67-76
71. Baker DG, Nievergelt CM, O'Connor DT. Biomarkers of ptsd: neuropeptides and immune signaling. Neuropharmacology 2012;62(2):663-73
72. Skelton K, Ressler KJ, Norrholm SD, et al. Ptsd and gene variants: new pathways and new thinking. Neuropharmacology 2012;62(2):628-37
73. Jovanovic T, Norrholm SD, Blanding NQ, et al. Impaired fear inhibition is a biomarker of ptsd but not depression. Depress Anxiety 2010;27(3):244-51
74. Milad MR, Pitman RK, Ellis CB, et al. Neurobiological basis of failure to recall extinction memory in posttraumatic stress disorder. Biol Psychiatry 2009;66(12):1075-82
75. Jovanovic T, Norrholm SD, Fennell JE, et al. Posttraumatic stress disorder may be associated with impaired fear inhibition: Relation to symptom severity. Psychiatry Res 2009;167(1-2):151-60
76. Grillon C, Morgan CA III. Fearpotentiated startle conditioning to explicit and contextual cues in gulf war veterans with posttraumatic stress disorder. J Abnorm Psychol 1999;108(1):134-42 (Pubitemid 29108316)
77. Orr SP, Metzger LJ, Lasko NB, et al. De novo conditioning in trauma-exposed individuals with and without posttraumatic stress disorder. J Abnorm Psychol 2000;109(2):290-8 (Pubitemid 30616926)
78. Jovanovic T, Ressler KJ. How the neurocircuitry and genetics of fear inhibition may inform our understanding of ptsd. Am J Psychiatry 2010;167(6):648-62
79. Quirk GJ, Russo GK, Barron JL, Lebron K. The role of ventromedial prefrontal cortex in the recovery of extinguished fear. J Neurosci 2000;20(16):6225-31 (Pubitemid 30658416)
80. Pitman RK, Delahanty DL. Conceptually driven pharmacologic approaches to acute trauma. CNS Spectr 2005;10(2):99-106 (Pubitemid 40327774)
81. Quirk GJ. Learning not to fear, faster. Learn Mem 2004;11(2):125-6 (Pubitemid 38456593)
82. Golub Y, Mauch CP, Dahlhoff M, Wotjak CT. Consequences of extinction training on associative and nonassociative fear in a mouse model of posttraumatic stress disorder (ptsd). Behav Brain Res 2009;205(2):544-9
83. Casada JH, Amdur R, Larsen R, Liberzon I. Psychophysiologic responsivity in posttraumatic stress disorder: generalized hyperresponsiveness versus trauma specificity. Biol Psychiatry 1998;44(10):1037-44 (Pubitemid 28545232)
84. van der Kolk BA. Clinical implications of neuroscience research in ptsd. Ann N Y Acad Sci 2006;1071:277-93 (Pubitemid 44126736)
85. Institute of Medicine. Treatment of posttraumatic stress disorder: An assessment of the evidence. Press Release 2008
86. Sharpless BA, Barber JP. A clinician's guide to ptsd treatments for returning veterans. Prof Psychol Res Pr 2011;42(1):8-15
87. Cukor J, Olden M, Lee F, Difede J. Evidence-based treatments for ptsd, new directions, and special challenges. Ann N Y Acad Sci 2010;1208:82-9
88. Choi DC, Rothbaum BO, Gerardi M, Ressler KJ. Pharmacological enhancement of behavioral therapy: Focus on posttraumatic stress disorder. Curr Top Behav Neurosci 2010;2:279-99
89. Bouton ME, Kenney FA, Rosengard C. State-dependent fear extinction with two benzodiazepine tranquilizers. Behavioral Neuroscience 1990;104:44-55 (Pubitemid 20138261)
90. Pratchett LC, Daly K, Bierer LM, Yehuda R. New approaches to combining pharmacotherapy and psychotherapy for posttraumatic stress disorder. Expert Opin Pharmacother 2011;12(15):2339-54
91. Ravindran LN, Stein MB. Pharmacotherapy of post-traumatic stress disorder. Curr Top Behav Neurosci 2010;2:505-25
92. Stein MB, Kerridge C, Dimsdale JE, Hoyt DB. Pharmacotherapy to prevent ptsd: results from a randomized controlled proof-of-concept trial in physically injured patients. J Trauma Stress 2007;20(6):923-32
93. Stein DJ, Zungu-Dirwayi N, van Der Linden GJ, Seedat S. Pharmacotherapy for posttraumatic stress disorder. Cochrane Database Syst Rev 2000;4:CD002795
94. Post-traumatic stress disorder: the management of ptsd in adults and children in primary and secondary care. British Psychological Society; London: 2005
95. Stein DJ, Ipser J, McAnda N. Pharmacotherapy of posttraumatic stress disorder: a review of meta-analyses and treatment guidelines. CNS Spectr 2009;14(1 Suppl 1):25-31
96. Ipser J, Seedat S, Stein DJ. Pharmacotherapy for post-traumatic stress disorder - a systematic review and meta-analysis. S Afr Med J 2006;96(10):1088-96 (Pubitemid 44649837)
97. Ursano RJ, Bell C, Eth S, et al. Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. Am J Psychiatry 2004;161(11 Suppl):3-31
98. Londborg PD, Hegel MT, Goldstein S, et al. Sertraline treatment of posttraumatic stress disorder: results of 24 weeks of open-label continuation treatment. J Clin Psychiatry 2001;62(5):325-31 (Pubitemid 32545552)
99. Karpova NN, Pickenhagen A, Lindholm J, et al. Fear erasure in mice requires synergy between antidepressant drugs and extinction training. Science 2011;334(6063):1731-4
100. Schneier FR, Neria Y, Pavlicova M, et al. Combined prolonged exposure therapy and paroxetine for ptsd related to the world trade center attack: a randomized controlled trial. Am J Psychiatry 2012;169(1):80-8
101. Wang W, Liu Y, Zheng H, et al. A modified single-prolonged stress model for post-traumatic stress disorder. Neurosci Lett 2008;441(2):237-41
102. Inoue T, Kitaichi Y, Koyama T. Ssris and conditioned fear. Prog Neuropsychopharmacol Biol Psychiatry 2011;35(8):1810-19
103. Davidson J, Baldwin D, Stein DJ, et al. Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. Arch Gen Psychiatry 2006;63(10):1158-65 (Pubitemid 44498394)
104. Davidson J, Rothbaum BO, Tucker P, et al. Venlafaxine extended release in posttraumatic stress disorder: a sertralineand placebo-controlled study. J Clin Psychopharmacol 2006;26(3):259-67 (Pubitemid 43804617)
105. Yang CH, Shi HS, Zhu WL, et al. Venlafaxine facilitates between-session extinction and prevents reinstatement of auditory-cue conditioned fear. Behav Brain Res 2012;230(1):268-73
106. U.S. Departments of Veterans Affairs and Defense. Clinical Practice Guideline for the Management of Post-Traumatic Stress; 2010
107. Klemenhagen KC, Gordon JA, David DJ, et al. Increased fear response to contextual cues in mice lacking the 5-ht1a receptor. Neuropsychopharmacology 2006;31(1):101-11 (Pubitemid 43250945)
108. Duffy JD, Malloy PF. Efficacy of buspirone in the treatment of posttraumatic stress disorder: an open trial. Ann Clin Psychiatry 1994;6(1):33-7 (Pubitemid 24222615)
109. Wells BG, Chu CC, Johnson R, et al. Buspirone in the treatment of posttraumatic stress disorder. Pharmacotherapy 1991;11(4):340-3
110. LaPorta LD, Ware MR. Buspirone in the treatment of posttraumatic stress disorder. J Clin Psychopharmacol 1992;12(2):133-4
111. Hamner M, Ulmer H, Horne D. Buspirone potentiation of antidepressants in the treatment of ptsd. Depress Anxiety 1997;5(3):137-9 (Pubitemid 28079916)
112. Adamec R, Bartoszyk GD, Burton P. Effects of systemic injections of vilazodone, a selective serotonin reuptake inhibitor and serotonin 1a receptor agonist, on anxiety induced by predator stress in rats. Eur J Pharmacol 2004;504(1-2):65-77 (Pubitemid 39410725)
113. Jiang X, Zhang ZJ, Zhang S, et al. 5-ht2a receptor antagonism by mdl 11, 939 during inescapable stress prevents subsequent exaggeration of acoustic startle response and reduced body weight in rats. J Psychopharmacol 2011;25(2):289-97
114. Davis LL, Jewell ME, Ambrose S, et al. A placebo-controlled study of nefazodone for the treatment of chronic posttraumatic stress disorder: a preliminary study. J Clin Psychopharmacol 2004;24(3):291-7 (Pubitemid 38658037)
115. Davidson JR, Weisler RH, Butterfield MI, et al. Mirtazapine vs. Placebo in posttraumatic stress disorder: a pilot trial. Biol Psychiatry 2003;53(2):188-91 (Pubitemid 36126484)
116. Kakui N, Yokoyama F, Yamauchi M, et al. Anxiolytic-like profile of mirtazapine in rat conditioned fear stress model: functional significance of 5-hydroxytryptamine 1a receptor and alpha1-adrenergic receptor. Pharmacol Biochem Behav 2009;92(3):393-8
117. Villard V, Meunier J, Chevallier N, Maurice T. Pharmacological interaction with the sigma1 (sigma1)-receptor in the acute behavioral effects of antidepressants. J Pharmacol Sci 2011;115(3):279-92
118. Sessa B. Is there a case for mdma-assisted psychotherapy in the uk? J Psychopharmacol 2007;21(2):220-4 (Pubitemid 46280475)
119. Mithoefer MC, Wagner MT, Mithoefer AT, et al. The safety and efficacy of {+/-} 3, 4-methylenedioxymethamphetamineassisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol 2011;25(4):439-52
120. den Hollander B, Schouw M, Groot P, et al. Preliminary evidence of hippocampal damage in chronic users of ecstasy. J Neurol Neurosurg Psychiatry 2012;83(1):83-5
121. Taylor FB, Martin P, Thompson C, et al. Prazosin effects on objective sleep measures and clinical symptoms in civilian trauma posttraumatic stress disorder: a placebo-controlled study. Biol Psychiatry 2008;63(6):629-32 (Pubitemid 351273194)
122. Raskind MA, Thompson C, Petrie EC, et al. Prazosin reduces nightmares in combat veterans with posttraumatic stress disorder. J Clin Psychiatry 2002;63(7):565-8 (Pubitemid 34787320)
123. Raskind MA, Peskind ER, Hoff DJ, et al. A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder. Biol Psychiatry 2007;61(8):928-34 (Pubitemid 46505008)
124. Peskind ER, Bonner LT, Hoff DJ, Raskind MA. Prazosin reduces traumarelated nightmares in older men with chronic posttraumatic stress disorder. J Geriatr Psychiatry Neurol 2003;16(3):165-71 (Pubitemid 37409027)
125. Byers MG, Allison KM, Wendel CS, Lee JK. Prazosin versus quetiapine for nighttime posttraumatic stress disorder symptoms in veterans: an assessment of long-term comparative effectiveness and safety. J Clin Psychopharmacol 2010;30(3):225-9
126. Taylor FB, Lowe K, Thompson C, et al. Daytime prazosin reduces psychological distress to trauma specific cues in civilian trauma posttraumatic stress disorder. Biol Psychiatry 2006;59(7):577-81 (Pubitemid 43357950)
127. Boynton L, Bentley J, Strachan E, et al. Preliminary findings concerning the use of prazosin for the treatment of posttraumatic nightmares in a refugee population. J Psychiatr Pract 2009;15(6):454-9
128. Bernardi RE, Lattal KM. A role for alpha-adrenergic receptors in extinction of conditioned fear and cocaine conditioned place preference. Behav Neurosci 2010;124(2):204-10
129. Lazzaro SC, Cain CK, Cunha C, LeDoux JE. Terazosin, an alpha1 adrenergic receptor antagonist, enhances acquisition and impairs extinction, but does not affect consolidation of pavlovian cue fear. Soc Neurosci Abstr 2009;479:22
130. Reist C, Duffy JG, Fujimoto K, Cahill L. Beta-adrenergic blockade and emotional memory in ptsd. Int J Neuropsychopharmacol 2001;4(4):377-83 (Pubitemid 33151681)
131. Pitman RK, Sanders KM, Zusman RM, et al. Pilot study of secondary prevention of posttraumatic stress disorder with propranolol. Biol Psychiatry 2002;51(2):189-92 (Pubitemid 34127909)
132. Vaiva G, Ducrocq F, Jezequel K, et al. Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma. Biol Psychiatry 2003;54(9):947-9 (Pubitemid 37311359)
133. Nugent NR, Christopher NC, Crow JP, et al. The efficacy of early propranolol administration at reducing ptsd symptoms in pediatric injury patients: a pilot study. J Trauma Stress 2010;23(2):282-7
134. Hoge EA, Worthington JJ, Nagurney JT, et al. Effect of acute posttrauma propranolol on ptsd outcome and physiological responses during scriptdriven imagery. CNS Neurosci Ther 2012;18(1):21-7
135. McGaugh JL, McIntyre CK, Power AE. Amygdala modulation of memory consolidation: interaction with other brain systems. Neurobiol Learn Mem 2002;78(3):539-52 (Pubitemid 36268676)
136. Debiec J, LeDoux JE. Disruption of reconsolidation but not consolidation of auditory fear conditioning by noradrenergic blockade in the amygdala. Neuroscience 2004;129(2):267-72 (Pubitemid 39388847)
137. Bush DE, Caparosa EM, Gekker A, Ledoux J. Beta-adrenergic receptors in the lateral nucleus of the amygdale contribute to the acquisition but. not the consolidation of auditory fear conditioning. Front Behav Neurosci 2010;4:154
138. Brunet A, Orr SP, Tremblay J, et al. Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder. J Psychiatr Res 2008;42(6):503-6 (Pubitemid 351240920)
139. Kindt M, Soeter M, Vervliet B. Beyond extinction: erasing human fear responses and preventing the return of fear. Nat Neurosci 2009;12(3):256-8
140. Schiller D, Phelps EA. Does reconsolidation occur in humans? Front Behav Neurosci 2011;5:24
141. Mueller D, Porter JT, Quirk GJ. Noradrenergic signaling in infralimbic cortex increases cell excitability and strengthens memory for fear extinction. J Neurosci 2008;28(2):369-75
142. Soeter M, Kindt M. Stimulation of the noradrenergic system during memory formation impairs extinction learning but not the disruption of reconsolidation. Neuropsychopharmacology 2012;37(5):1204-15
143. Cain CK, Blouin AM, Barad M. Adrenergic transmission facilitates extinction of conditional fear in mice. Learn Mem 2004;11(2):179-87 (Pubitemid 38456600)
144. Morris RW, Bouton ME. The effect of yohimbine on the extinction of conditioned fear: a role for context. Behav Neurosci 2007;121(3):501-14 (Pubitemid 47445103)
145. Powers MB, Smits JA, Otto MW, et al. Facilitation of fear extinction in phobic participants with a novel cognitive enhancer: a randomized placebo controlled trial of yohimbine augmentation. J Anxiety Disord 2009;23(3):350-6
146. Hefner K, Whittle N, Juhasz J, et al. Impaired fear extinction learning and cortico-amygdala circuit abnormalities in a common genetic mouse strain. J Neurosci 2008;28(32):8074-85
147. Rudy JW, Kuwagama K, Pugh CR. Isolation reduces contextual but not auditory-cue fear conditioning: a role for endogenous opioids. Behav Neurosci 1999;113(2):316-23 (Pubitemid 29230940)
148. Walker DL, Ressler KJ, Lu KT, Davis M. Facilitation of conditioned fear extinction by systemic administration or intraamygdala infusions of d-cycloserine as assessed with fear-potentiated startle in rats. J Neurosci 2002;22(6):2343-51 (Pubitemid 35386533)
149. Heresco-Levy U, Kremer I, Javitt DC, et al. Pilot-controlled trial of d-cycloserine for the treatment of post-traumatic stress disorder. Int J Neuropsychopharmacol 2002;5(4):301-7 (Pubitemid 35470350)
150. Heresco-Levy U, Ermilov M, Shimoni J, et al. Placebo-controlled trial of dcycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. Am J Psychiatry 2002;159(3):480-2 (Pubitemid 34184748)
151. Aerni A, Traber R, Hock C, et al. Low-dose cortisol for symptoms of posttraumatic stress disorder. Am J Psychiatry 2004;161(8):1488-90 (Pubitemid 38989105)
152. Jovanovic T, Phifer JE, Sicking K, et al. Cortisol suppression by dexamethasone reduces exaggerated fear responses in posttraumatic stress disorder. Psychoneuroendocrinology 2011;36(10):1540-52
153. Miller MW, McKinney AE, Kanter FS, et al. Hydrocortisone suppression of the fear-potentiated startle response and posttraumatic stress disorder. Psychoneuroendocrinology 2011;36(7):970-80
154. Weis F, Kilger E, Roozendaal B, et al. Stress doses of hydrocortisone reduce chronic stress symptoms and improve health-related quality of life in high-risk patients after cardiac surgery: a randomized study. J Thorac Cardiovasc Surg 2006;131(2):277-82
155. Schelling G, Kilger E, Roozendaal B, et al. Stress doses of hydrocortisone, traumatic memories, and symptoms of posttraumatic stress disorder in patients after cardiac surgery: a randomized study. Biol Psychiatry 2004;55(6):627-33 (Pubitemid 38315037)
156. Schelling G, Briegel J, Roozendaal B, et al. The effect of stress doses of hydrocortisone during septic shock on posttraumatic stress disorder in survivors. Biol Psychiatry 2001;50(12):978-85 (Pubitemid 34066490)
157. Suris A, North C, Adinoff B, et al. Effects of exogenous glucocorticoid on combat-related ptsd symptoms. Ann Clin Psychiatry 2010;22(4):274-9
158. Kehne JH, Cain CK. Therapeutic utility of non-peptidic crf(1) receptor antagonists in anxiety, depression, and stress-related disorders: evidence from animal models. Pharmacol Ther 2010
159. Deak T, Nguyen KT, Ehrlich AL, et al. The impact of the nonpeptide corticotropin-releasing hormone antagonist antalarmin on behavioral and endocrine responses to stress. Endocrinology 1999;140(1):79-86 (Pubitemid 29011144)
160. Yang YL, Chao PK, Ro LS, et al. Glutamate nmda receptors within the amygdala participate in the modulatory effect of glucocorticoids on extinction of conditioned fear in rats. Neuropsychopharmacology 2007;32(5):1042-51
161. Bernardy NC, Lund BC, Alexander B, Friedman MJ. Prescribing trends in veterans with posttraumatic stress disorder. J Clin Psychiatry 2012;73(3):297-303
162. Hartley CA, Phelps EA. Changing fear: the neurocircuitry of emotion regulation. Neuropsychopharmacology 2010;35(1):136-46
163. Walderhaug E, Kasserman S, Aikins D, et al. Effects of duloxetine in treatmentrefractory men with posttraumatic stress disorder. Pharmacopsychiatry 2010;43(2):45-9
164. Villarreal G, Canive JM, Calais LA, et al. Duloxetine in military posttraumaticstress disorder. Psychopharmacol Bull 2010;43(3):26-34
165. Raskind MA, Peskind ER, Kanter ED, et al. Reduction of nightmares and other ptsd symptoms in combat veterans by prazosin: a placebo-controlled study. Am J Psychiatry 2003;160(2):371-3 (Pubitemid 41110467)
166. Davis LL, Ward C, Rasmusson A, et al. A placebo-controlled trial of guanfacine for the treatment of posttraumatic stress disorder in veterans. Psychopharmacol Bull 2008;41(1):8-18
167. Neylan TC, Lenoci M, Samuelson KW, et al. No improvement of posttraumatic stress disorder symptoms with guanfacine treatment. Am J Psychiatry 2006;163(12):2186-8 (Pubitemid 46114243)
168. Kinzie JD, Leung P. Clonidine in cambodian patients with posttraumatic stress disorder [see comments]. J Nerv Ment Dis 1989;177(9):546-50 (Pubitemid 19233931)
169. Becker ME, Hertzberg MA, Moore SD, et al. A placebo-controlled trial of bupropion sr in the treatment of chronic posttraumatic stress disorder. J Clin Psychopharmacol 2007;27(2):193-7 (Pubitemid 46594938)
170. Krystal JH, Rosenheck RA, Cramer JA, et al. Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related ptsd: a randomized trial. JAMA 2011;306(5):493-502
171. Rothbaum BO, Killeen TK, Davidson JR, et al. Placebo-controlled trial ofrisperidone augmentation for selective serotonin reuptake inhibitor-resistant civilian posttraumatic stress disorder.J Clin Psychiatry 2008;69(4):520-5 (Pubitemid 351792325)
172. Padala PR, Madison J, Monnahan M, et al. Risperidone monotherapy for posttraumatic stress disorder related to sexual assault and domestic abuse in women. Int Clin Psychopharmacol 2006;21(5):275-80 (Pubitemid 44162479)
173. Kozaric-Kovacic D, Pivac N, Muck-Seler D, Rothbaum BO. Risperidone in psychotic combat-related posttraumatic stress disorder: an open trial. J Clin Psychiatry 2005;66(7):922-7 (Pubitemid 41032835)
174. Bartzokis G, Lu PH, Turner J, et al. Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder. Biol Psychiatry 2005;57(5):474-9 (Pubitemid 40311981)
175. Reich DB, Winternitz S, Hennen J, et al. A preliminary study of risperidone in the treatment of posttraumatic stress disorder related to childhood abuse in women. J Clin Psychiatry 2004;65(12):1601-6
176. David D, De Faria L, Lapeyra O, Mellman TA. Adjunctive risperidonetreatment in combat veterans with chronic ptsd. J Clin Psychopharmacol 2004;24(5):556-9 (Pubitemid 39274216)
177. Monnelly EP, Ciraulo DA, Knapp C, Keane T. Low-dose risperidone as adjunctive therapy for irritable aggression in posttraumatic stress disorder. J Clin Psychopharmacol 2003;23(2):193-6 (Pubitemid 36368797)
178. Kozaric-Kovacic D, Pivac N. Quetiapine treatment in an open trial in combatrelated post-traumatic stress disorder with psychotic features. Int J Neuropsychopharmacol 2007;10(2):253-61
179. Ahearn EP, Mussey M, Johnson C, et al. Quetiapine as an adjunctive treatment for post-traumatic stress disorder: an 8-week open-label study. Int Clin Psychopharmacol 2006;21(1):29-33 (Pubitemid 43175120)
180. Robert S, Hamner MB, Kose S, et al. Quetiapine improves sleep disturbances in combat veterans with ptsd: sleep data from a prospective, open-label study. J Clin Psychopharmacol 2005;25(4):387-8 (Pubitemid 41060262)
181. Hamner MB, Deitsch SE, Brodrick PS, et al. Quetiapine treatment in patients with posttraumatic stress disorder: an open trial of adjunctive therapy. J Clin Psychopharmacol 2003;23(1):15-20 (Pubitemid 36164420)
182. Davidson J, Kudler H, Smith R, et al. Treatment of posttraumatic stress disorder with amitriptyline and placebo. Arch Gen Psychiatry 1990;47(3):259-66 (Pubitemid 20086679)
183. Frank JB, Kosten TR, Giller EL Jr, Dan E. A randomized clinical trial of phenelzine and imipramine for posttraumatic stress disorder. Am J Psychiatry 1988;145(10):1289-91
184. Kosten TR, Frank JB, Dan E, et al. Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. J Nerv Ment Dis 1991;179(6):366-70
185. Pivac N, Kozaric-Kovacic D, Muck-Seler D. Olanzapine versus fluphenazine in an open trial in patients with psychotic combat-related post-traumatic stress disorder. Psychopharmacology (Berl) 2004;175(4):451-6 (Pubitemid 39362043)
186. Stein MB, Kline NA, Matloff JL. Adjunctive olanzapine for ssri-resistant combat-related ptsd: a double-blind, placebo-controlled study. Am J Psychiatry 2002;159(10):1777-9
187. Petty F, Brannan S, Casada J, et al. Olanzapine treatment for post-traumatic stress disorder: an open-label study. Int Clin Psychopharmacol 2001;16(6):331-7 (Pubitemid 33030048)
188. Butterfield MI, Becker ME, Connor KM, et al. Olanzapine in the treatment ofpost-traumatic stress disorder: a pilot study. Int Clin Psychopharmacol 2001;16(4):197-203 (Pubitemid 32612517)
189. Robert S, Hamner MB, Durkalski VL, et al. An open-label assessment of aripiprazole in the treatment of ptsd. Psychopharmacol Bull 2009;42(1):69-80
190. Mello MF, Costa MC, Schoedl AF, Fiks JP. Aripiprazole in the treatment of posttraumatic stress disorder: an open-label trial. Rev Bras Psiquiatr 2008;30(4):358-61
191. Villarreal G, Calais LA, Canive JM, et al. Prospective study to evaluate the efficacy of aripiprazole as a monotherapy in patients with severe chronic posttraumatic stress disorder: an open trial. Psychopharmacol Bull2007;40(2):6-18
192. Holbrook TL, Galarneau MR, Dye JL, et al. Morphine use after combat injury in iraq and post-traumatic stress disorder. N Engl J Med 2010;362(2):110-17
193. Bryant RA, Creamer M, O'Donnell M, et al. A study of the protective function of acute morphine administration on subsequent posttraumatic stress disorder. Biol Psychiatry 2009;65(5):438-40
194. Stoddard FJ Jr, Sorrentino EA, Ceranoglu TA, et al. Preliminary evidence for the effects of morphine on posttraumatic stress disorder symptoms in one- to four-year-olds with burns.J Burn Care Res 2009;30(5):836-43
195. Saxe G, Stoddard F, Courtney D, et al. Relationship between acute morphine and the course of ptsd in children with burns. J Am Acad Child Adolesc Psychiatry 2001;40(8):915-21 (Pubitemid 32667074)
196. Glover H. A preliminary trial of nalmefene for the treatment of emotional numbing in combat veterans with posttraumatic stress disorder. Isr J Psychiatry Relat Sci 1993;30(4):255-63 (Pubitemid 24039004)
197. Lubin G, Weizman A, Shmushkevitz M, Valevski A. Short-term treatment of posttraumatic stress disorder with naltrexone: an open-label preliminary study. Hum Psychopharmacol 2002;17(4):181-5 (Pubitemid 34678879)
198. Henn-Haase HC, Best BS, Metzler MT, et al. Exposure based cbt therapy and dcycloserinetreatment for ptsd in veterans and civilians. 2010
199. Guay GS, Marchand MA, Landry LP. Results from a six-month follow-up of a randomized controlled trial assessing the efficacy of cognitive-behavior therapy combined with d-cycloserine for treating ptsd. 2010
200. Schonenberg M, Reichwald U, Domes G, et al. Ketamine aggravates symptoms of acute stress disorder in a naturalistic sample of accident victims. J Psychopharmacol 2008;22(5):493-7
201. McGhee LL, Maani CV, Garza TH, et al. The correlation between ketamine and posttraumatic stress disorder in burned service members. J Trauma 2008;64(2 Suppl):S195-8; Discussion S197-198
202. Tucker P, Trautman RP, Wyatt DB, et al. Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, doubleblind, placebo-controlled study. J Clin Psychiatry 2007;68(2):201-6 (Pubitemid 46362640)
203. Lindley SE, Carlson EB, Hill K. A randomized, double-blind, placebocontrolled trial of augmentation topiramate for chronic combat-related posttraumatic stress disorder. J Clin Psychopharmacol 2007;27(6):677-81 (Pubitemid 351339456)
204. Berlant J, van Kammen DP. Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: a preliminary report. J Clin Psychiatry 2002;63(1):15-20 (Pubitemid 34113481)
205. Hertzberg MA, Butterfield MI, Feldman ME, et al. A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol Psychiatry 1999;45(9):1226-9 (Pubitemid 29236566)
206. Davidson JR, Brady K, Mellman TA, et al. The efficacy and tolerability of tiagabine in adult patients with posttraumatic stress disorder. J Clin Psychopharmacol 2007;27(1):85-8 (Pubitemid 46105772)
207. Connor KM, Davidson JR, Weisler RH, et al. Tiagabine for posttraumatic stressdisorder: effects of open-label and double-blind discontinuation treatment. Psychopharmacology (Berl) 2006;184(1):21-5 (Pubitemid 43005753)
208. Davis LL, Davidson JR, Ward LC, et al. Divalproex in the treatment of posttraumatic stress disorder: a randomized, double-blind, placebocontrolled trial in a veteran population. J Clin Psychopharmacol 2008;28(1):84-8
209. Hamner MB, Brodrick PS, Labbate LA. Gabapentin in ptsd: a retrospective, clinical series of adjunctive therapy. Ann Clin Psychiatry 2001;13(3):141-6 (Pubitemid 34020148)
210. Kinrys G, Wygant LE, Pardo TB, MeloM. Levetiracetam for treatment-refractory posttraumatic stress disorder. J Clin Psychiatry 2006;67(2):211-14 (Pubitemid 43357466)
211. Pollack MH, Hoge EA, Worthington JJ, et al. Eszopiclone for the treatment of posttraumatic stress disorder and associated insomnia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2011;72(7):892-7
212. Gelpin E, Bonne O, Peri T, et al. Treatment of recent trauma survivors with benzodiazepines: a prospective study. J Clin Psychiatry 1996;57(9):390-4 (Pubitemid 26321989)
213. Braun P, Greenberg D, Dasberg H, Lerer B. Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment. J Clin Psychiatry 1990;51(6):236-8 (Pubitemid 20209219)
214. Cates ME, Bishop MH, Davis LL, et al. Clonazepam for treatment of sleep disturbances associated with combat-related posttraumatic stress disorder. Ann Pharmacother 2004;38(9):1395-9 (Pubitemid 39100190)
215. Mellman TA, Bustamante V, David D, Fins AI. Hypnotic medication in the aftermath of trauma. J Clin Psychiatry 2002;63(12):1183-4
216. Mathew SJ, Vythilingam M, Murrough JW, et al. A selective neurokinin-1 receptor antagonist in chronic ptsd: A randomized, double-blind, placebo-controlled, proof-of-concept trial. Eur Neuropsychopharmacol 2011;21(3):221-9
217. Kehne JH. The crf1 receptor, a novel target for the treatment of depression, anxiety, and stress-related disorders. CNS Neurol Disord Drug Targets 2007;6(3):163-82 (Pubitemid 46916249)